Circadian Genes and Risk for Prostate Cancer
Annual rept. 1 Sep 2009-31 Aug 2010
TRUE RESEARCH FOUNDATION SAN ANTONIO TX
Pagination or Media Count:
We propose that genetic susceptibility to prostate cancer may be in part due to variations in the core circadian genes that regulate circadian rhythms and that serum sex steroid hormone levels modify the effect of circadian gene polymorphisms on prostate cancer risk. Our study is nested within the Prostate Cancer Prevention Trial PCPT, a randomized placebo-controlled clinical trial to determine if finasteride an inhibitor of androgen bioactivation could prevent prostate cancer. In Year 2 of the award, we were approved by the DoD to changed our contracting genotyping facility to the University of Texas Health Science Center at San Antonio UTHSCSA, which was mandated by the PCPT executive committee, and have been involved in analyzing serum androgen data that will be used for Aim 2 of our study. We have been working with the UTHSCSA to ensure that the genotyping assays for our study using the new genotyping platform will be successful. We have also had the DNA samples re-plated at the PCPT biorepository and shipped to UTHSCSA for genotyping.
- Anatomy and Physiology
- Medicine and Medical Research